secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001420720-25-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio develops Activin E antibody for obesity; preclinical data shows sub-nanomolar binding
--------------------------------------------------------------------------------

- Antibody targeting Activin E for cardiometabolic disorders and obesity, developed with AstralBio Inc.
- Preclinical data: sub-nanomolar binding kinetics and complete blockade of Activin E signaling in human adipocytes.
- Utilized iBio's AI platform to engineer antibodies targeting five epitopes on Activin E protein.
- Corporate presentation updated to reflect the new antibody program; used in investor meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000003/0001420720-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000003/ibio-20250110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer